Ipsc Derived Oligodendrocytes is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Induced pluripotent stem cell (iPSC)-derived oligodendrocytes are glial cells generated from patient-specific or healthy donor-derived iPSCs that can myelinate axons in the central nervous system. These cells offer unprecedented opportunities for disease modeling of demyelinating disorders, drug screening, and potentially cell replacement therapy for conditions like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS)[1][2].
| Property |
Value |
| Category |
Stem Cell-Derived Glia |
| Origin |
Induced Pluripotent Stem Cells |
| Lineage |
Neural Progenitor → Oligodendrocyte Progenitor → Mature Oligodendrocyte |
| Key Markers |
OLIG2, SOX10, MBP, PLP1, O4 |
| Function |
Myelin production, axonal support |
| Disease Relevance |
Multiple Sclerosis, ALS, Periventricular Leukomalacia |
Generating oligodendrocytes from iPSCs involves a multi-stage process that recapitulates embryonic development:
- Neural induction: Directing iPSCs toward neural fate
- Patterning: Ventral neural tube patterning for oligodendrocyte lineage
- Expansion: Proliferating oligodendrocyte progenitor cells (OPCs)
- Maturation: Differentiating into myelinating oligodendrocytes
- SHH (Sonic Hedgehog): Critical for ventral patterning
- FGF2 (Fibroblast Growth Factor 2): OPC proliferation
- PDGF-AA (Platelet-Derived Growth Factor): OPC survival and proliferation
- T3 (Triiodothyronine): Oligodendrocyte maturation
- CNTF (Ciliary Neurotrophic Factor): Maturation enhancement
- BMP inhibitors: Blocking astrocyte differentiation
OPCs are the transit-amplifying stage between neural progenitors and mature oligodendrocytes:
- Proliferative: Can divide and expand in culture
- Migratory: Can migrate to demyelinated areas
- Plastic: Can dedifferentiate under certain conditions
- PDGFRA (PDGF Receptor Alpha): Early OPC marker
- NG2 (CSPG4): Chondroitin sulfate proteoglycan
- OLIG2: Transcription factor
- NKX2.2: Homeobox transcription factor
- SOX10: Sustains oligodendrocyte lineage
Mature oligodendrocytes produce myelin sheaths that wrap around axons:
- MBP (Myelin Basic Protein): Structural stability
- PLP1 (Proteolipid Protein 1): Major myelin protein
- MAG (Myelin-Associated Glycoprotein): Axonal recognition
- MOG (Myelin Oligodendrocyte Glycoprotein): Surface marker
- Saltatory conduction: Enables rapid nerve impulse transmission
- Metabolic support: Provides lactate to axons
- Axonal maintenance: Prevents axonal degeneration
- Ion homeostasis: Regulates extracellular potassium
iPSC-derived oligodendrocytes model MS pathology:
- Demyelination mechanisms: Understanding immune-mediated myelin loss
- Remyelination failure: Why endogenous OPCs fail to repair
- Drug screening: Identifying compounds that enhance myelination
- Patient-specific models: Genetic variants affecting disease severity
Oligodendrocyte dysfunction in ALS:
- Reduced myelin production: Early feature of ALS pathology
- Metabolic support loss: Contributes to motor neuron degeneration
- SOD1 models: Reveals oligodendrocyte-specific vulnerabilities
- TDP-43 pathology: Oligodendrocyte involvement in protein aggregation
Neonatal white matter injury:
- Preterm infant models: Understanding hypoxic-ischemic injury
- Developmental myelination: How injury affects myelin development
- Therapeutic interventions: Strategies to protect oligodendrocytes
iPSC-derived oligodendrocytes enable drug discovery:
- Remyelination compounds: Screen for myelin regeneration
- Anti-inflammatory agents: Reduce immune attack on oligodendrocytes
- Neuroprotective drugs: Protect oligodendrocytes from death
- Differentiation enhancers: Promote OPC maturation
- Clemastine: Antihistamine promoting OPC differentiation
- Miconazole: Antifungal enhancing myelination
- Benztropine: Anti-parkinsonian with remyelination potential
- Opicinumab: Anti-LINGO-1 antibody in clinical trials
Oligodendrocyte transplantation aims to repair demyelinated lesions:
- OPC transplantation: Less mature cells may integrate better
- Direct oligodendrocyte delivery: Mature cells for rapid myelination
- Biomaterial scaffolds: Enhance cell survival and integration
- Combination approaches: Cells plus neurotrophic factors
- Survival: Low survival rates after transplantation
- Migration: Limited spread from injection site
- Maturation: Ensuring proper differentiation
- Immune response: Rejection of allogeneic cells
- Tumorigenicity: Risk of uncontrolled proliferation
- Patient-specific disease modeling possible with iPSCs
- Autologous transplantation feasible
- Similar differentiation efficiency
- Both require purification for clinical use
- iPSC-derived OPCs may have greater proliferative capacity
- Adult OPCs already committed to oligodendrocyte lineage
- iPSCs can be gene-corrected before differentiation
- Both face similar transplantation challenges
- 3D brain organoids: Incorporating oligodendrocytes in assembloids
- Single-cell profiling: Understanding heterogeneity
- Gene editing: Correcting disease-causing mutations
- Automated platforms: Scalable manufacturing
- iPSC banks: Clinical-grade cell lines for allogeneic therapy
- xenogeneic-free media: Clinical-grade differentiation protocols
- Non-integrating reprogramming: Safety improvements
- Disease-in-a-dish: Personalized medicine applications
The study of Ipsc Derived Oligodendrocytes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Wang et al. Efficient derivation of oligodendrocytes from ESCs (Nature Biotechnology, 2013)
- Najm et al. Scalable production of OPCs (Nature Methods, 2015)
- Douvaras et al. iPSC-derived oligodendrocytes from MS patients (Cell Stem Cell, 2014)
- Trotter et al. Oligodendrocyte differentiation protocols (J Neurosci Methods, 2019)
- Pandiyan et al. ALS oligodendrocyte pathology (Acta Neuropathol, 2022)
- Chen et al. Remyelination drug screening (Nature, 2021)